- Details
- Martin King and David Yang join Zachary Klaassen to discuss their study on AI-derived tumor volume assessment in prostate cancer MRI. The research demonstrates how their AI model successfully segments and measures prostate tumors from MRI images, showing strong prognostic value for cancer outcomes in both radiation and surgery patients. The study reveals that AI-derived tumor volume serves as an i...
|
- Details
- Zachary Klaassen and Luke Nordquist discuss the CLARIFY trial, which evaluates a novel Copper-64 SAR-bisPSMA PET imaging technique for high-risk prostate cancer patients before surgery. Dr. Nordquist explains the trial's focus on patients with aggressive disease features who are scheduled for surgery within 90 days, highlighting the advantage of Copper-64's longer half-life which allows for imagin...
|
- Details
- An engaging Q&A session follows Matthew Cooperberg's discussion with pathologists Jesse McKenney and Jane Nguyen about their prostate cancer histology classification system. The conversation explores how this new approach might interface with emerging AI technologies and genomic tests like Decipher, while addressing practical questions about implementation and accessibility. The experts clarify th...
|
- Details
- Matthew Cooperberg hosts a discussion with Jesse McKenney and Jane Nguyen about research on prostate cancer grading, presented in a paper proposing a new definition of adverse pathology. Dr. McKenney details how their work challenges traditional Gleason grading systems by introducing a simplified "favorable" versus "unfavorable" histology classification, primarily based on cribriform patterns in t...
|
- Details
- Mark Sultan and Eric Kim discuss research on predicting prostate cancer progression during active surveillance using Decipher® genomic classifier scores and MRI characteristics. Their study reveals that while both high Decipher® scores and high-risk MRI findings independently predict progression, these markers are weakly correlated, suggesting they capture distinct risk information. The conversati...
|
- Details
- Amy Pearlman discusses penile traction therapy using the RestoreX device, a second-generation technology designed to address penile length changes after prostate cancer treatment. Dr. Pearlman explains how this device, developed by Dr. Landon Trost at Mayo Clinic, offers advantages over first-generation devices through its dynamic stretching capabilities and shorter required usage times. The discu...
|
- Details
- Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation. The discussion emphasizes the importance of early intervention and ongoing maintenance to preserve penile health, comparing the penis to a sponge that requires regular blood flow to maintain its struct...
|
- Details
- At the 2024 LUGPA annual meeting, Arvin George presents focal therapy's role in prostate cancer, highlighting patient selection criteria, treatment options like HIFU and cryotherapy, and its advantages over radical treatments. He emphasizes its potential in salvage settings post-radiation, while noting the need for long-term studies. Biographies: Arvin George, MD, Urologic Surgeon, Johns Hopkins M...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Martin Gleave reviews risk stratification challenges in high-risk prostate cancer, highlighting current system limitations. He proposes a four-tier framework incorporating tumor volume, grade patterns, PSA levels, and PSMA PET findings to guide treatment intensification decisions. Biographies: Martin E. Gleave, CM, MD, FRCSC, FACS,...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Declan Murphy discusses DRE's evolving role in prostate cancer detection and staging. While noting its limited value in primary care and MRI-accessible settings, he emphasizes DRE's continued importance in regions lacking advanced imaging technologies. Biographies: Declan Murphy, Urologist and Director of Genitourinary Oncology, Pe...
|
